TipRanks3 “Strong Buy” Stocks That Are Flirting With a BottomIn the investing recreation, it’s not solely about what you purchase; it’s about whenever you purchase it. One of the crucial frequent items of recommendation thrown across the Street, “buy low” is touted as a tried-and-true tactic.Positive, the technique appears easy. Stock costs naturally fluctuate on the idea of a number of components like earnings outcomes and the macro setting, amongst others, with buyers attempting to time the market and decide when stocks have hit a backside. In apply, nonetheless, executing on this technique is not any straightforward process.On high of this, given the volatility that has dominated the markets over the previous couple of weeks, how are buyers purported to gauge when a reputation is flirting with a backside? That’s the place the Wall Street execs are available in.These professional stock pickers have recognized three compelling tickers whose present share costs land near their 52-week lows. Noting that every is about to take again off on an upward trajectory, the analysts see a beautiful entry level. Utilizing TipRanks’ database, we came upon that the analyst consensus has rated all three a Robust Purchase, with main upside potential additionally on faucet.Progenity (PROG)Providing clear and actionable genetic outcomes, Progenity makes a speciality of offering testing providers. The corporate began buying and selling on Nasdaq in June and noticed its shares tumbling 44% since then. With shares altering arms for $8.11, a number of members of the Street suggest pulling the set off earlier than it heats up.Piper Sandler analyst Steven Mah factors out that even in opposition to the backdrop of COVID-19, PROG managed to ship with its Q2 2020 efficiency. “We are encouraged by the recovery in late Q2 2020 with 75,000 accessioned tests (~79,000 in Q1 2020), driven by noninvasive prenatal testing (NIPT) and carrier screening,” the analyst famous. Expounding on this, Mah said, “Progenity did not provide guidance, but June test volumes of ~28,000 were strong (Q1 2020 monthly average was ~26,000) which we believe showcases the durability of its reproductive tests and the success that Progenity has in co-marketing and attaching carrier screening to the more essential NIPT. Of note, despite the pandemic disruptions, Progenity was able to maintain its leading pre-COVID test turnaround times.”Moreover, well being insurer Aetna is briefly extending protection of average-risk NIPT till year-end because of the pandemic, with the American School of Obstetricians and Gynecologists (ACOG) additionally anticipated to endorse average-risk sooner or later given its medical utility, in Mah’s opinion.Reflecting one other optimistic, the fourth era NIPT (single-molecule counting assay) check was capable of measure fetal fraction, a key milestone based on Mah, and can proceed to be developed into 2021. Because the know-how may doubtlessly be utilized to DNA, RNA, epigenetic markers and proteins for extra medical purposes similar to oncology, the analyst is wanting ahead to the completion of the preeclampsia verification in This fall 2020 and a attainable 2H21 launch. “We believe preeclampsia (~2.3 billion serviceable market) is a major differentiator for Progenity, allowing them to cross-sell across the full-continuum of reproductive testing,” the analyst added.If that wasn’t sufficient, PROG signed its first GI Precision Medication partnership settlement with a top-20 Pharma firm in August. The Oral Biotherapeutic Supply System (OBDS), an ingestible drug and machine mixture designed to exactly ship biologics systemically by a needle-free liquid jet injection into the submucosal tissues of the small gut, is about to be utilized as a part of the collaboration. Mah commented, “We believe Progenity can sign additional Pharma deals and look forward to the newsflow coming out on this front.”To sum all of it up, Mah stated, “We believe Progenity shares are undervalued given the robust recovery in the core testing business and multiple upcoming growth catalysts.”To this finish, Mah charges PROG an Obese (i.e. Purchase) together with a $17 price goal. Ought to his thesis play out, a twelve-month acquire of 105% may doubtlessly be within the playing cards. (To look at Mah’s monitor document, click on right here)Are different analysts in settlement? They’re. Solely Purchase scores, 4, the truth is, have been issued within the final three months. Due to this fact, the message is obvious: PROG is a Robust Purchase. Given the $13.33 common price goal, shares may climb 60% greater within the subsequent yr. (See PROG stock evaluation on TipRanks)Tactile Programs Know-how (TCMD)Growing at-home remedy gadgets, Tactile Programs Know-how needs to offer new remedies for lymphedema, which happens when the lymphatic system is impaired, disrupting regular transport of fluid inside the physique, and power venous insufficiency. Down 52% year-to-date, its $32.67 share price lands near its $29.47 52-week low. Thus, with enterprise traits enhancing, the Street is pounding the desk.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the corporate, with COVID-19 weighing on each volumes and gross sales. Within the second half of March, volumes have been down 50% in comparison with the primary half of the month, and TCMD’s affected person volumes in April and May remained challenged. That being stated, traits began to enhance on the finish of May.“Going forward, given the vast majority of TCMD’s clinician customers practice in outpatient or office-based settings, we remain positive on TCMD’s ability to demonstrate better insulation against COVID impacts and likely experience a greater bounce-back relative to overall med-tech volume trends, with TCMD further benefitting from its expanding using of technology to remotely engage with clinicians and support patients,” Furlong defined.The analyst added, “Furthermore, recent trends among some providers to prescribe Flexitouch (an advanced intermittent pneumatic compression device to self-manage lymphedema and nonhealing venous leg ulcers) earlier along the therapy process, as a means to reduce in-person contact, could provide upside near term, as well as potentially transition to a longer-term tailwind.”On high of this, Furlong can be optimistic about new CEO Dan Reuvers and the reprioritization of the corporate’s funding and market improvement efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments towards its Flexitouch and Entre (a pneumatic compression machine used to help within the house administration of power swelling and venous ulcers related to lymphedema and power venous insufficiency) merchandise.“Given significant under-penetration in the lymphedema/phlebolymphedema market targeted by Flexitouch alongside the large patient population with limited treatment options today targeted by the firm’s Head & Neck platform, we view the combination of education and clinical data as key to further developing and penetrating these markets… Going forward, we expect management to continue to compile a broad base of clinical data to support reimbursement and drive broad adoption,” Furlong commented.All of this prompted Furlong to maintain a Purchase score and $62 price goal on the stock. This goal conveys her confidence in TCMD’s means to soar 90% within the subsequent yr. (To look at Furlong’s monitor document, click on right here)Normally, different analysts are on the identical web page. With three Purchase scores and 1 Maintain, the phrase on the Street is that TCMD is a Robust Purchase. The $62.33 common price goal brings the upside potential to 91%. (See TCMD stock evaluation on TipRanks)uniQure N.V. (QURE)Final however not least we’ve uniQure, which delivers healing gene therapies that would doubtlessly remodel the lives of sufferers. Although shares have fallen 44% year-to-date to $40, not a lot greater than its 52-week low of $36.20, a number of analysts nonetheless have excessive hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after information broke of its collaboration and licensing settlement with CSL Behring for AMT-061, QURE’s gene remedy for Hemophilia B, he argues the “shareholder base turnover is likely now complete as investors and QURE shift focus to next-in-line AMT-130, its AAV5 gene therapy for Huntington’s Disease (HD).”Schwartz additional added, “With the M&A premium now out of the stock, we see the QURE’s current level as an attractive buying opportunity for those investors interested in the company’s up and coming CNS gene therapies, internal manufacturing, and robust intellectual property and knowhow.”Wanting extra intently on the settlement with CSL Behring, QURE might be tasked with the completion of the pivotal Part three HOPE-B trial in addition to the manufacturing course of validation and manufacturing provide of AMT-061.In line with administration, 26-week Issue IX (FIX) knowledge from all 54 sufferers enrolled within the trial stays on monitor, and topline knowledge from the pivotal trial continues to be slated to learn out by YE20. It ought to be talked about that in a Part 2b dose-confirmation research, QURE reported 41% FIX exercise out to 1 yr. Moreover, Schwartz factors out that with HOPE-B progressing as deliberate, QURE has continued its manufacturing course of validation work forward of the anticipated BLA/MAA submissions within the U.S. and EU in 2021.On high of this, as a part of the deal, QURE is eligible to obtain greater than $2 billion together with a $450 million upfront cash cost, $1.6 billion in regulatory and industrial milestones and double-digit royalties ranging as much as the low-twenties proportion of internet product gross sales.“With a strengthened cash position, QURE is well funded to rapidly advance CNS assets including AMT-130 (AAV5 gene therapy for Huntington’s Disease (HD)) and AMT-150 (AAV gene therapy for Spinocerebellar Ataxia Type 3/SCA3)…We continue to believe that as QURE’s CNS pipeline assets mature, the company could once again be an attractive partner to larger biopharma companies that have recently acquired many publicly traded gene therapy platforms with substantial manufacturing capabilities,” Schwartz famous.Every little thing that QURE has going for it satisfied Schwartz to reiterate an Outperform (i.e. Purchase) score. Together with the decision, he hooked up a $67 price goal, suggesting 68% upside potential from present ranges. (To look at Schwartz’s monitor document, click on right here)What does the remainder of the Street need to say? 9 Buys and three Holds have been issued within the final three months, so the consensus score is a Robust Purchase. As well as, the $69.89 common price goal signifies 75% upside potential. (See QURE stock evaluation on TipRanks)To search out good concepts for beaten-down stocks buying and selling at engaging valuations, go to TipRanks’ Greatest Stocks to Purchase, a newly launched instrument that unites all of TipRanks’ fairness insights.Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is vitally essential to do your personal evaluation earlier than making any funding.